Fennec Pharmaceuticals Inc. (FENC)

Market Cap	127.29M
Revenue (ttm)	49.35M
Net Income (ttm)	-1.13M
Shares Out	27.43M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,809
Open	4.250
Previous Close	4.275
Day's Range	4.210 - 4.790
52-Week Range	3.960 - 11.920
Beta	0.27
Analysts	Strong Buy
Price Target	14.00 (+201.72%)
Earnings Date	Nov 7, 2024

About FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is ba...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2001
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: FENC
• Website: https://www.fennecpharma.com

Financial Performance

In 2023, Fennec Pharmaceuticals's revenue was $21.25 million, an increase of 1284.50% compared to the previous year's $1.54 million. Losses were -$16.05 million, -32.34% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is $14.0, which is an increase of 201.72% from the latest price.

Price Target

$14.0

(201.72% upside)

Analyst Consensus: Strong Buy